To test this, we evaluated cell viability, invasive capacity, and the acquisition of a NE-like phenotype in prostate cancer cell lines cultured under androgen-deprived conditions and in the presence of a PPARG selective antagonist. This evidence concerns the gene PPARG and prostate carcinoma.